Jun 2026 (Q2 FY26) — Aug 6, 2026
Verastem, Inc. Q2 FY26 — Strong Commercial Rebound and Pipeline Advancement
Read the full callVerastem (VSTM) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Verastem earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 40.1 | +1775.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -81.6 | +1966.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -34.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$8.62 −0.35% · −$0.03
Performance −6.5% 1Y
1Y: $9.22 on 17 Oct 2025 → $8.62. High $10.64 (28 Nov 2025), low $3.45 (25 Jun 2026).
- Previous close
- $8.65
- 52-week range
- $3.45 – $10.64
- One year
- +7.48%
Overview
- Symbol
- VSTM
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Verastem earnings calls (VSTM)
Financials
What the filings say
Net profit, year on year: −34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | 0 | — | 2 | 11 | 18 | 19 | 40 |
| Expenses | 37 | 32 | 44 | 46 | 52 | 59 | 64 | 73 |
| Operating profit | -37 | -32 | -44 | -44 | -41 | -41 | -45 | -33 |
| Operating margin | — | — | — | −2047.9% | −362.2% | −236.5% | −240.5% | −81.6% |
| Interest | 1 | 1 | 0 | 0 | 0 | — | 0 | 0 |
| Profit before tax | — | — | — | -26 | — | — | — | -34 |
| Tax rate | — | — | — | — | — | — | — | −2.4% |
| Net profit | -24 | -65 | -52 | -26 | -99 | -33 | -37 | -35 |
| EPS ($ per share) | -0.60 | — | -0.96 | -0.39 | -1.35 | — | -0.37 | -0.35 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -376 | -525 | -593 | -664 | -738 | -825 | -956 | -1,165 |
| Total liabilities | 153 | 138 | 39 | 21 | 48 | 71 | 130 | 189 |
| Fixed assets | 1 | 1 | 0 | 0 | 0 | 0 | 0 | — |
| Total assets | 277 | 145 | 154 | 109 | 95 | 150 | 102 | 246 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -75 | -139 | -34 | -54 | -64 | -86 | -105 | -138 |
| Cash from investing | -138 | 90 | -47 | 0 | 66 | -44 | 60 | -10 |
| Cash from financing | 261 | -2 | 70 | 7 | 52 | 134 | 55 | 263 |
| Net cash flow | 48 | -51 | -11 | -47 | 54 | 3 | 10 | 116 |
| Capital expenditure | -2 | -0 | -0 | -0 | — | — | -0 | — |
| Free cash flow | -76 | -139 | -34 | -54 | — | — | -105 | — |
Insider filings
47 filings between Nov 3, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.09M
33 sales by 6 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Paterson Dan | — | $855.1K | Oct 1, 2026 |
| Kauffman Michael | — | $85.5K | Nov 21, 2025 |
| Calkins Daniel | — | $74.7K | Oct 1, 2026 |
| Bunn Paul A. | — | $62.5K | Nov 21, 2025 |
| Stuglik Brian M | — | $5.4K | Dec 16, 2025 |
| Gagnon Robert E. | — | $2.6K | Dec 16, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 2,566 | $20.5K |
| Oct 1, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 44,121 | $353.0K |
| Sep 30, 2026 | Calkins Daniel Chief Financial Officer | Award 10b5-1 plan | 8,333 | $0 |
| Sep 30, 2026 | Paterson Dan President and CEO | Award 10b5-1 plan | 106,893 | $0 |
| Sep 21, 2026 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 55 | $424 |
| Aug 3, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 1,302 | $7.6K |
| Jun 22, 2026 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 57 | $235 |
| Jun 22, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 20,871 | $87.2K |
| Jun 22, 2026 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 4,032 | $16.9K |
| May 21, 2026 | BAILEY MICHAEL P Director | Award | 108,000 | $0 |
| May 21, 2026 | JOHNSON JOHN Director | Award | 36,000 | $0 |
| May 21, 2026 | Tollefson Karin Anna Director | Award | 36,000 | $0 |
| May 21, 2026 | Bunn Paul A. Director | Award | 36,000 | $0 |
| May 21, 2026 | Stuglik Brian M Director | Award | 36,000 | $0 |
| May 21, 2026 | Rowinsky Eric K Director | Award | 36,000 | $0 |
| May 21, 2026 | ROBERTSON MICHELLE Director | Award | 36,000 | $0 |
| May 21, 2026 | Kapur Anil Director | Award | 36,000 | $0 |
| May 4, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 806 | $4.7K |
| Mar 20, 2026 | Calkins Daniel Chief Financial Officer | Award 10b5-1 plan | 57 | $327 |
| Feb 4, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 970 | $6.5K |
| Jan 21, 2026 | Calkins Daniel Chief Financial Officer | Award | 16,665 | $0 |
| Jan 21, 2026 | Paterson Dan President and CEO | Award | 213,785 | $0 |
| Jan 12, 2026 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 5,039 | $36.1K |
| Jan 12, 2026 | Paterson Dan President and CEO | Sale 10b5-1 plan | 10,321 | $73.9K |
| Dec 24, 2025 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 80 | $629 |
| Dec 16, 2025 | Gagnon Robert E. Director | Sale 10b5-1 plan | 283 | $2.6K |
| Dec 16, 2025 | Stuglik Brian M Director | Sale 10b5-1 plan | 592 | $5.4K |
| Dec 16, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 393 | $3.6K |
| Dec 11, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Dec 10, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.1K |
| Dec 9, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.5K |
| Dec 8, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $21.0K |
| Dec 5, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $21.2K |
| Dec 4, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Dec 3, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Dec 2, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.6K |
| Dec 1, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.8K |
| Nov 28, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $21.6K |
| Nov 26, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.6K |
| Nov 25, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Nov 24, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Nov 21, 2025 | Bunn Paul A. Director | Option exercise 10b5-1 plan | 6,250 | $20.4K |
| Nov 21, 2025 | Kauffman Michael Director | Sale 10b5-1 plan | 8,550 | $85.5K |
| Nov 21, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Nov 21, 2025 | Bunn Paul A. Director | Sale 10b5-1 plan | 6,250 | $62.5K |
| Nov 3, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 1,299 | $12.1K |
| Nov 3, 2025 | Paterson Dan President and CEO | Sale 10b5-1 plan | 2,000 | $20.0K |
| Oct 9, 2025 | Bunn Paul A. Director | Sale 10b5-1 plan | 8,333 | $75.5K |
| Sep 24, 2025 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 25 | $231 |
| Sep 22, 2025 | Calkins Daniel Chief Financial Officer | Sale 10b5-1 plan | 57 | $518 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Verastem, Inc.
Free account. Everything above stays public.
Write why you follow Verastem, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading